<DOC>
	<DOCNO>NCT01787357</DOCNO>
	<brief_summary>The purpose study assess effect canagliflozin ( JNJ-28431754 ) electrocardiogram result ( recordings electrical activity heart ) healthy volunteer single therapeutic dose ( 300 mg ) single supra-therapeutic dose ( 4 time high [ 1,200 mg ] anticipate therapeutic dose 300 mg ) . The safety tolerability canagliflozin also assess .</brief_summary>
	<brief_title>A Study Assess Electrocardiogram Results Healthy Volunteers Receiving Canagliflozin ( JNJ-28431754 )</brief_title>
	<detailed_description>This study randomize ( treatment assign chance ) , single-center , double-blind ( neither investigator volunteer know identity assign treatment ) , double-dummy ( technique retaining blind nature study treatment look identical ) , placebo-controlled ( one treatment inactive ) , positive-controlled ( one treatment know potential effect electrocardiogram result ) , four-way cross-over study ( volunteer receive 4 treatment different order ) ass effect canagliflozin ( drug currently investigate treatment type 2 diabetes mellitus ) electrocardiogram result healthy volunteer . The study consist 3 phase : screening phase , double-blind treatment phase , end-of study ( follow-up ) phase . Volunteers assign 1 4 treatment sequence group ( ADBC , DABC , BCDA , CDAB ) . The treatment sequence decide randomization . Treatment A single dose 300 mg canagliflozin . Treatment B single dose 1,200 mg canagliflozin . Treatment C single dose placebo ( inactive medication ) . Treatment D single dose 400 mg moxifloxacin ( antibiotic know potential affect electrocardiogram result ) . Each treatment give treatment period 2 day duration ; treatment period separate washout period ( medication give ) 10 14 day . Each volunteer participate study approximately 61 day .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Volunteers must body mass index ( BMI = weight kg/height m2 ) 18 35 kg/m2 ( inclusive ) body weight less 50 kg Volunteers must average triplicate 12lead electrocardiogram ( ECG ) recording , take maximum 2 minute recording , consistent normal cardiac conduction function , specify protocol Volunteers must nonsmoker History currently active illness consider clinically significant Investigator illness Investigator considers exclude patient study could interfere interpretation study result History additional risk factor presence family history Short QT Syndrome , Long QT Syndrome , sudden unexplained death young age ( &lt; =40 year ) , drown sudden infant death syndrome first degree relative ( ie , biological parent , sibling , child )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Electrocardiogram Parameters</keyword>
	<keyword>QT/QTc Interval</keyword>
	<keyword>Therapeutic dose</keyword>
	<keyword>Supra-Therapeutic dose</keyword>
</DOC>